Last reviewed · How we verify
Placebo matching Tamsulosine Arrow LP
This is a placebo formulation designed to match the appearance and administration profile of Tamsulosin Arrow LP, a selective alpha-1A adrenergic receptor antagonist used in benign prostatic hyperplasia treatment.
This is a placebo formulation designed to match the appearance and administration profile of Tamsulosin Arrow LP, a selective alpha-1A adrenergic receptor antagonist used in benign prostatic hyperplasia treatment. Used for Clinical trial control for benign prostatic hyperplasia studies.
At a glance
| Generic name | Placebo matching Tamsulosine Arrow LP |
|---|---|
| Sponsor | Pierre Fabre Medicament |
| Drug class | Placebo (matching formulation) |
| Modality | Small molecule |
| Therapeutic area | Urology |
| Phase | FDA-approved |
Mechanism of action
As a placebo, this product contains no active pharmaceutical ingredient and is used as a control in clinical trials. The matched formulation mimics Tamsulosin Arrow LP's extended-release delivery system and physical characteristics to maintain blinding in randomized controlled studies. Tamsulosin itself works by blocking alpha-1A receptors on smooth muscle in the prostate and bladder neck, reducing urinary obstruction symptoms.
Approved indications
- Clinical trial control for benign prostatic hyperplasia studies
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo matching Tamsulosine Arrow LP CI brief — competitive landscape report
- Placebo matching Tamsulosine Arrow LP updates RSS · CI watch RSS
- Pierre Fabre Medicament portfolio CI